Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.53 |
| ▸ | MLNR | O43193 | 1/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21118548 | 0.81 | SLC6A3 (0.59) | SLC6A4SLC6A3SLC6A2MLNRCACNA1F | |
| SCHEMBL21118698 | 0.80 | SLC6A3 (0.55) | SLC6A4SLC6A3SLC6A2MLNRCACNA1F | |
| Duloxetine SCHEMBL3335 | 0.74 | SLC6A2 (0.87) | SLC6A4SLC6A3SLC6A2MLNRCACNA1F | |
| Duloxetine SCHEMBL2120068 | 0.74 | SLC6A2 (0.87) | SLC6A4SLC6A3SLC6A2MLNRCACNA1F | |
| Duloxetine SCHEMBL3896385 | 0.74 | SLC6A2 (0.87) | SLC6A4SLC6A3SLC6A2MLNRCACNA1F | |
| Duloxetine SCHEMBL308488 | 0.74 | SLC6A2 (0.87) | SLC6A4SLC6A3SLC6A2MLNRCACNA1F | |
| SCHEMBL21118802 | 0.73 | SLC6A3 (0.56) | SLC6A4SLC6A3SLC6A2MLNRCACNA1F | |
| SCHEMBL21118553 | 0.73 | SLC6A4 (0.64) | SLC6A4SLC6A3SLC6A2MLNRCACNA1F | |
| Duloxetine SCHEMBL4573554 | 0.73 | SLC6A2 (0.85) | SLC6A4SLC6A3SLC6A2MLNRCACNA1F | |
| Duloxetine SCHEMBL3649623 | 0.72 | SLC6A2 (0.80) | SLC6A4SLC6A3SLC6A2MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111220-B2 | Propanamine derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-09-07 | — | — | US | disclosed |
| US-20200377464-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377464-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1G, CACNA1B, CACNA1I | SLC6A4 173/4885SLC6A3 175/4885SLC6A2 39/4885 |
| US-11111220-B2 | Propanamine derivatives for treating pain and pain related conditions | CACNA1G, CACNA1B, CACNA1I | SLC6A4 173/4885SLC6A3 175/4885SLC6A2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.